Status:
UNKNOWN
Tofacitinib Versus Methotrexate as the First Line DMARD in the Treatment of Rheumatoid Arthritis
Lead Sponsor:
Dr. Mohammad Mamun Khan
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
It is a randomized controlled study
Detailed Description
Randomization controlled study on Rheumatoid arthritis patients whos disease activity is high, controlled subjects will be given methotrexate and study subjects will get tofacitinib
Eligibility Criteria
Inclusion
- age greater than 18 years 2. patients fulfill the ACR-EULAR classification criteria for RA 3.DAS-28 CRP more than 5.1
- \-
Exclusion
- systemic infection
- hemoglobin less than 9 mg/dl
- WBC \<4000, neutrophil \<1000, platelet \<100000/mm
- live vaccine within 3 months
- GFR \< 50 ml/min
- ALT \> 2 times ULN
- pregnancy
Key Trial Info
Start Date :
July 10 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2020
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT04464642
Start Date
July 10 2019
End Date
September 1 2020
Last Update
July 9 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bangabandhu Seikh Mujib Medical University
Dhaka, Bangladesh